Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Thromb Res ; 213: 78-83, 2022 05.
Article in English | MEDLINE | ID: mdl-35306431

ABSTRACT

BACKGROUND: Neutrophil extracellular traps (NETs) are formed by DNA, histones and proteolytic enzymes, and are produced by activated neutrophils through different mechanisms. In turn, NETs can activate platelets and coagulation cascade favoring thrombotic processes. The aims of this study were to analyze levels and kinetics of NETs in ST-segment elevation myocardial infarction (STEMI) patients and correlate them with antithrombotic therapy and cardiovascular outcomes at follow-up. METHODS: 150 consecutive STEMI patients referred to primary percutaneous coronary intervention (pPCI) were included. Citrate anticoagulated blood was extracted immediately before pPCI, 30 min and 24 h after the procedure. As markers of NETS cell free DNA (cfDNA), nucleosomes and citrullinated Histone 3 (citH3) were determined. 46 healthy subjects were included as controls. Patients were follow-up for 1.4 ± 0.56 years. RESULTS: Before pPCI, NETs markers were elevated in STEMI patients compared to healthy controls (p < 0.05); these increased significantly 30 min post pPCI (p ≤ 0.001) and decreased at 24 h but remained elevated compared with the control group (p < 0.05). Patients treated with bivalirudin presented a lower increase of NETs 30 min post pPCI compared to patients treated with heparin (p < 0.05). Cardiovascular risk factors or type of stent implanted did not modify NETs levels. Cit3H (HR = 3.74; 95%CI 1.05-13.4; p = 0.042) and left ventricular ejection fraction ≤35% (HR = 6.84; 95%CI 2-23; p = 0.002) were independent predictors of composite endpoint of myocardial infarction, stroke, stent thrombosis and/or cardiovascular-cause death. CONCLUSIONS: NETs were elevated in STEMI patients, increased by pPCI and decreased thereafter. One of the most specific NETs markers was associated with cardiovascular outcomes.


Subject(s)
Extracellular Traps , Myocardial Infarction , Percutaneous Coronary Intervention , ST Elevation Myocardial Infarction , Extracellular Traps/metabolism , Fibrinolytic Agents , Humans , Myocardial Infarction/metabolism , ST Elevation Myocardial Infarction/drug therapy , ST Elevation Myocardial Infarction/surgery , Stroke Volume , Treatment Outcome , Ventricular Function, Left
3.
Thromb Haemost ; 117(10): 1919-1929, 2017 10 05.
Article in English | MEDLINE | ID: mdl-28837206

ABSTRACT

Neutrophil extracellular traps (NETs) are networks of DNA, histones, and proteolytic enzymes produced by activated neutrophils through different mechanisms. NET formation is promoted by activated platelets and can in turn activate platelets, thus favoring thrombotic processes. NETs have been detected in venous and arterial thrombosis, but data in stroke are scarce. The aim of this study was to evaluate NETs in the plasma of patients with acute ischemic stroke and their potential association with baseline clinical characteristics, stroke severity, and one-year clinical outcomes. The study included 243 patients with acute ischemic stroke. Clinical and demographic data and scores of stroke severity (NIHSS and mRs) at onset and discharge were recorded. Markers of NETs (cell-free DNA, nucleosomes, and citrullinated histone 3 (citH3)), were determined in plasma. Patients were followed-up for 12 months after the ischemic event. NETs were significantly elevated in the plasma of patients with acute ischemic stroke when compared to healthy subjects. NETs were increased in patients who were over 65 years of age and in those with a history of atrial fibrillation (AF), cardioembolic stroke, high glucose levels, and severe stroke scores at admission and discharge. In multivariate analysis, elevated levels of citH3, the most specific marker of NETs, at onset were independently associated with AF and all-cause mortality at one-year follow-up. NETs play a role in the pathophysiology of stroke and are associated with severity and mortality. In conclusion, citH3 may constitute a useful prognostic marker and therapeutic target in patients with acute stroke.


Subject(s)
Brain Ischemia/blood , Extracellular Traps/metabolism , Stroke/blood , Aged , Aged, 80 and over , Biomarkers/blood , Brain Ischemia/diagnosis , Brain Ischemia/mortality , Brain Ischemia/therapy , Case-Control Studies , Cause of Death , Chi-Square Distribution , Citrulline/blood , Female , Histones/blood , Humans , Logistic Models , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Prognosis , Risk Factors , Severity of Illness Index , Stroke/diagnosis , Stroke/mortality , Stroke/therapy , Time Factors , Up-Regulation
5.
Curr Opin Oncol ; 27(6): 522-31, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26447878

ABSTRACT

PURPOSE OF REVIEW: In this article, we summarize the current knowledge on new roles played by platelets and their interactions with blood components, and their possible implications in malignant hematological disorders. RECENT FINDINGS: Recent reports in the literature are revealing that platelets are important partners in different aspects of physiology and pathophysiology beyond hemostasis and thrombosis, including but not restricted to inflammation, cancer or host defense. Moreover, several studies suggest that platelet interactions with other blood cells could regulate functional and biochemical responses of each other. Finally, platelet alterations in number as well as in function have been observed in different hematological disorders related with the action of treatments. SUMMARY: Common complications of leukemia are bleeding and thrombosis, in which the number and activity of platelets undoubtedly play an important role. Probably related with their apparent structural simplicity compared with other hematological cells, the interest in platelets in malignant hematological disorders has been mainly restricted to the determination of the number of circulating platelets. However, different studies have demonstrated that numbers of platelets between 6 and 80 × 10(9) platelets/l are a poor indicator of the risk of bleeding, as this number does not give any information on the functional activity of these platelets.


Subject(s)
Blood Platelets/physiology , Hematologic Neoplasms/physiopathology , Hematologic Neoplasms/immunology , Hemostatic Disorders/physiopathology , Humans , Immunity, Cellular/physiology , Inflammation/blood , Thrombosis/physiopathology
6.
Neurol Res ; 37(8): 688-92, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25916560

ABSTRACT

OBJECTIVES: It has been suggested that metalloproteinase-9 (MMP-9) could predict the onset of cerebral vasospasm after subarachnoidal haemorrhage (SAH). The aim of this study was to analyse, in patients with SAH, the difference between patients with MRI ischaemic infarcts and patients without, and to investigate the role of metalloproteases as a prognostic factor for ischaemic infarcts. METHODS: Sixty eight consecutive patients with SAH and diffusion-weighted magnetic resonance imaging (DWI-MRI) done 3 weeks after SAH. We define two groups, with and without DWI-MRI infarcts. Blood samples were taken at entry, 3 days and 1 week MMP-9 was determined through ELISA method. RESULTS: Forty per cent were male, with a mean age of 54 ± 14 years. Twenty five patients, 36.8%, had DWI-MRI infarcts; in patients with MRI infarcts, SAH was more severe (Fisher = 4 52 vs 25.6%, P = 0.037), with more morbi-mortality (Rankin>3 48 vs 18.6%, P = 0.014), and more symptomatic vasospasm (28 vs 7%, P = 0.031). Levels of MMP-9 were higher than controls, but there were no significant differences between patients with and without infarcts (first determination no infarcts 39.40 ng/ml ± 35.40 vs infarcts 49.75 ng/ml ± 34.54, P > 0.005, 3 days no infarcts 72.10 ng/ml ± 70.95 vs infarcts 62.28 ± 33.84, P > 0.005, 1 week no infarcts 148.48 ng/ml ± 142.73 vs infarcts 91.5 ng/ml ± 1.20, P > 0.005). CONCLUSION: Thirty eight percent in a well-studied series of patients with SAH have DWI-MRI infarcts; the infarcts were associated to SAH severity, SAH outcome and symptomatic vasospasm. Metalloproteinase-9 was higher in SAH patients than in controls, but it could not discriminate the infarct patients.


Subject(s)
Brain/pathology , Cerebral Infarction/blood , Cerebral Infarction/pathology , Matrix Metalloproteinase 9/blood , Subarachnoid Hemorrhage/blood , Subarachnoid Hemorrhage/pathology , Adult , Biomarkers/blood , Cerebral Infarction/complications , Cerebral Infarction/mortality , Diffusion Magnetic Resonance Imaging , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Prognosis , Severity of Illness Index , Subarachnoid Hemorrhage/complications , Subarachnoid Hemorrhage/mortality
7.
J Stroke Cerebrovasc Dis ; 23(10): 2794-2799, 2014.
Article in English | MEDLINE | ID: mdl-25440364

ABSTRACT

BACKGROUND: Platelet inhibition measured by platelet function tests could be critical to understand the reasons for early recurrence and to guide therapeutic recommendations. We assess the platelet function during the acute phase of ischemic stroke in patients pretreated with aspirin who continue their treatment with aspirin only, are started on clopidogrel only, or add clopidogrel to aspirin. METHODS: Sixty-four patients were taking aspirin before the stroke. Depending on the administered antiplatelet, 3 groups were defined: ASA: patients who continued on aspirin orally or intravenous acetylsalicylate of lysine, n = 30; CLO: patients who discontinued aspirin and were started on clopidogrel, n = 16; and ASA + CLO: patients who were prescribed both aspirin and clopidogrel, n = 10. Collagen-induced thromboxane A2 (TXA2) synthesis, ADP (adenosine diphosphate)-induced aggregation, and occlusion time (PF-100) were measured. RESULTS: CLO group only had a marked elevation of TXA2 (17.44 ± 15.62 ng/mL, P = .000) and a shortening of the platelet function analyzer (PFA)-100 closure time (157.13 ± 88 seconds, P = .047) compared with the other 2 groups (ASA: TXA2, .62 ± 1.59 ng/mL; ASA + CLO: TXA2 1.79 ± 4.59 ng/mL). They achieved a small (13%) but significant reduction of ADP-induced aggregation (87.00 ± 23.06 mm, P = .008) compared with the ASA group (102.82 ± 22.38 seconds). CONCLUSIONS: Stopping aspirin intake within the first 72 hours of the acute stroke drastically increases TXA2 synthesis. During the same time window, the freshly prescribed clopidogrel manages to reduce the ADP-induced aggregation only slightly (13%). This study offers analytic proof that the common practice of replacing aspirin with clopidogrel does not leave stroke patients fully protected during the first days after an ischemic stroke. Possible solutions could be to preserve aspirin during a few days or to use loading doses of clopidogrel at hospital admission.


Subject(s)
Aspirin/administration & dosage , Blood Platelets/drug effects , Brain Ischemia/drug therapy , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation/drug effects , Platelet Function Tests , Stroke/drug therapy , Ticlopidine/analogs & derivatives , Aged , Aged, 80 and over , Aspirin/adverse effects , Biomarkers/blood , Blood Platelets/metabolism , Brain Ischemia/blood , Brain Ischemia/diagnosis , Clopidogrel , Drug Substitution , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Platelet Aggregation Inhibitors/adverse effects , Predictive Value of Tests , Stroke/blood , Stroke/diagnosis , Thromboxane A2/blood , Ticlopidine/administration & dosage , Ticlopidine/adverse effects , Time Factors , Treatment Outcome
8.
Platelets ; 25(4): 268-73, 2014.
Article in English | MEDLINE | ID: mdl-23909754

ABSTRACT

Abstract The optimal dose of aspirin for patients presenting with acute myocardial infarction (AMI) while receiving chronic aspirin therapy has not been clearly established. We evaluated whether continued treatment with 100 mg of aspirin or a loading dose (200-500 mg) influences thromboxane A2 (TX) suppression or platelet reactivity. Sixty-four consecutive patients with AMI and 98 healthy subjects (82 aspirin-free and 16 receiving 100 mg daily for a week) were evaluated. Treatment was at the discretion of the attending physician. Collagen (1 µg/ml)-induced TX synthesis, (14)C-serotonin-release, platelet aggregation, and the PFA-100 assay were evaluated. The platelet TX synthesis of patients receiving a loading dose of aspirin was sixfold lower than that of patients receiving 100 mg of aspirin (p<0.005). This was associated with marked reductions in (14)C-serotonin-release and arachidonic-acid-induced aggregation and an increase in the PFA-100 closure time (p<0.01). Categorization of patients according to their TX synthesis (<95% or ≥ 95% inhibition vs. healthy aspirin-free subjects) revealed that 8% of the patients treated with loading doses had a poor response (<95% inhibition) vs. 53% of those treated with 100 mg (p<0.001). Patients with lower TX inhibition had higher serum NT-Pro-BNP (p<0.005), a marker of poor left ventricular systolic function. Administration of a loading dose of aspirin to patients with AMI during existing chronic aspirin treatment induced greater reductions in platelet TX synthesis and TX-dependent platelet reactivity than the continued treatment alone.


Subject(s)
Aspirin/administration & dosage , Blood Platelets/drug effects , Blood Platelets/metabolism , Myocardial Infarction/drug therapy , Myocardial Infarction/metabolism , Platelet Aggregation Inhibitors/administration & dosage , Thromboxane A2/metabolism , Aged , Aged, 80 and over , Biomarkers/metabolism , Female , Humans , Male , Middle Aged , Myocardial Infarction/diagnosis , Platelet Activation/drug effects , Platelet Function Tests
9.
Life Sci ; 93(20): 707-13, 2013 Nov 06.
Article in English | MEDLINE | ID: mdl-24096143

ABSTRACT

AIMS: We studied the role of serine/threonine phosphatases (PSTPs) on αIIbß3 signaling and the potential selectivity of the level of PSTP inhibition with okadaic acid (OA) on αIIbß3 signaling for regulation of platelet aggregation and clot retraction. MAIN METHODS: We used washed platelets from normal donors and OA as inhibitor of PSTPs. Clot retraction was induced by 1U/mL of thrombin. Reorganized cytoskeleton was isolated from Triton X-100 lysed platelets. The presence of proteins incorporated to the cytoskeleton was assayed by immunoblotting with specific antibodies. KEY FINDINGS: We found that both 100 and 500 nM OA blocked platelet mediated clot retraction. In contrast, only 500 nM OA inhibited thrombin-induced inside-out αIIbß3 activation, platelet aggregation, and cytoskeletal reorganization. Among markers of αIIbß3 outside-in signaling, 500 nM OA inhibited the incorporation to the cytoskeleton of syk, src, and FAK (Focal Adhesion Kinase) tyrosine kinases and the incorporation and phosphorylation at Tyr(759) of the ß3 chain of αIIbß3, while 100 nM OA only inhibited the FAK translocation and its tyrosine phosphorylation. SIGNIFICANCE: The level of inhibition of PSTPs by low or high OA concentration (33% and 73% inhibition, respectively) in intact whole cells differentially regulates platelet aggregation and integrin signaling, but have a common effect in blocking clot retraction. The latter may be associated with the presence of phosphorylated FAK in the cytoskeleton. This study reveals a novel target for anti-platelet treatment to block clot retraction without affecting the platelet hemostatic function by a partial inhibition of PSTPs.


Subject(s)
Blood Platelets/drug effects , Clot Retraction/drug effects , Okadaic Acid/pharmacology , Phosphoprotein Phosphatases/antagonists & inhibitors , Phosphoprotein Phosphatases/metabolism , Platelet Glycoprotein GPIIb-IIIa Complex/metabolism , Blood Platelets/cytology , Blood Platelets/enzymology , Focal Adhesion Protein-Tyrosine Kinases/metabolism , Humans , Platelet Aggregation/drug effects , Signal Transduction/drug effects
10.
Curr Vasc Pharmacol ; 11(4): 431-47, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23905638

ABSTRACT

Platelets play an important role in both normal hemostasis and pathological thrombus formation. The key role of platelets in thrombosis is highlighted by the clinical benefit of treatment with antiplatelet drugs. Aspirin, either alone or in combination with clopidogrel in high-risk patients, is the most widely used antiplatelet agent. However, there is an individual response to these agents that may reduce the cardiovascular protection in patients who achieve a lower antiplatelet effect. Recently, P2Y12 receptor antagonists more potent than clopidogrel (e.g., prasugrel and ticagrelor) have been approved for patients with acute coronary syndromes and those undergoing percutaneous coronary interventions; these drugs provide greater platelet inhibition than clopidogrel. However, the increased effectiveness of these treatments has underscored the importance of carefully balancing the risks of ischemia and bleeding to achieve the best clinical outcomes. The increased knowledge of the molecular mechanisms of platelet activation has prompted a search for novel pharmacological targets for the inhibition of platelet reactivity. This article reviews the molecular mechanisms of action and limitations of use of current and emerging antiplatelet agents for treatment of cardiovascular disease.


Subject(s)
Blood Platelets/drug effects , Cardiovascular Diseases/drug therapy , Platelet Aggregation Inhibitors/pharmacology , Animals , Blood Platelets/metabolism , Cardiovascular Diseases/physiopathology , Drug Approval , Drug Design , Hemostasis , Humans , Molecular Targeted Therapy , Platelet Activation/drug effects , Platelet Aggregation Inhibitors/adverse effects , Platelet Aggregation Inhibitors/therapeutic use , Purinergic P2 Receptor Antagonists/adverse effects , Purinergic P2 Receptor Antagonists/pharmacology , Purinergic P2 Receptor Antagonists/therapeutic use , Thrombosis/drug therapy , Thrombosis/pathology
11.
Thromb Res ; 132(2): 211-6, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23830213

ABSTRACT

INTRODUCTION: The pharmacological target of aspirin is the inhibition of cyclooxygenase-1 (COX1) and thromboxane-A2 (TX) synthesis. Very few data are available on TX assessment in patients with stroke. We studied platelet TX synthesis, COX1-independent platelet reactivity, the influence of platelet-erythrocyte interactions and the potential association between platelet responses and the severity of stroke, evaluated with a clinical score (NIHSS). MATERIAL AND METHODS: We examined 157 aspirin-treated patients with acute stroke or TIA, 128 aspirin-free and 15 aspirin-treated healthy subjects (HS). Collagen-induced TX, platelet recruitment in whole blood and platelets ± erythrocytes (haematocrit 40%) were assessed in patients on daily-aspirin within three days from onset. Arachidonic-acid-, ADP-, thrombin-receptor activating peptide TRAP-, and collagen-induced aggregation were also evaluated. RESULTS: Partial TX inhibition (<95% inhibition vs aspirin-free controls) was observed in 13% of patients. This was associated with marked increases in COX1-dependent responses (arachidonic-acid- and collagen-induced aggregation and platelet recruitment; P<0.0001) but not with differences in ADP- or TRAP-induced aggregation. Partial TX inhibition was independently associated with severe stroke (NIHSS ≥ 12) at both admission (P<0.05) and discharge (P<0.05). Among patients with fully blocked TX, those with elevated COX1-independent platelet reactivity (mean+2SD of aspirin-treated HS) were most likely to suffer severe stroke (P<0.05). Platelet-erythrocyte interactions enhanced platelet reactivity in these patients by COX1-dependent and -independent mechanisms (P<0.0001). CONCLUSIONS: TX inhibition by aspirin varied across patients. Partial TX inhibition and COX1-independent platelet hyperfunction were associated with more-severe stroke.


Subject(s)
Aspirin/therapeutic use , Cyclooxygenase 1/biosynthesis , Ischemic Attack, Transient/blood , Ischemic Attack, Transient/drug therapy , Stroke/blood , Stroke/drug therapy , Thromboxane A2/biosynthesis , Acute Disease , Aged , Case-Control Studies , Cyclooxygenase 1/blood , Cyclooxygenase Inhibitors/therapeutic use , Female , Humans , Ischemic Attack, Transient/enzymology , Male , Platelet Aggregation/drug effects , Stroke/enzymology , Thromboxane A2/blood
12.
Eur J Pharmacol ; 708(1-3): 88-94, 2013 May 15.
Article in English | MEDLINE | ID: mdl-23461855

ABSTRACT

We tested the hypothesis that the phytoestrogen genistein protects the brain against ischemic stroke by improving the circulatory function in terms of reduced production of thromboxane A2 and leukocyte-platelet aggregates, and of preserved vascular reactivity. Ischemia-reperfusion (90 min-3 days, intraluminal filament) was induced in male Wistar rats, and functional score and cerebral infarct volume were the end points examined. Genistein (10mg/kg/day) or vehicle (ß-cyclodextrin) was administered at 30 min after ischemia or sham-operation. Production of thromboxane A2 and leukocyte-platelet aggregates, as well as reactivity of carotid artery to U-46619 (thromboxane A2 analogue) and to platelet releasate was measured. At 3 days post-ischemia, both improvement in the functional examination and reduction in the total infarct volume were shown in the ischemic genistein-treated group. Genistein significantly reverted both the increased thromboxane A2 concentration and the increased leukocyte-platelet aggregates production found in samples from the ischemic vehicle-treated group. Both U-46619 and platelet releasate elicited contractions of the carotid artery, which were significantly lower in the ischemic vehicle-treated group. Genistein significantly restored both the decreased U-46619- and the decreased platelet releasate-elicited contractile responses. In conclusion, genistein protects the brain against an ischemia-reperfusion challenge, at least in part, by its beneficial effects on the circulatory function.


Subject(s)
Brain Ischemia/drug therapy , Genistein/therapeutic use , Neuroprotective Agents/therapeutic use , Phytoestrogens/therapeutic use , Stroke/drug therapy , Animals , Brain Ischemia/complications , Brain Ischemia/metabolism , Brain Ischemia/pathology , Genistein/blood , Genistein/pharmacology , Male , Neuroprotective Agents/blood , Neuroprotective Agents/pharmacology , Phytoestrogens/blood , Phytoestrogens/pharmacology , Platelet Aggregation/drug effects , Rats , Rats, Wistar , Stroke/etiology , Stroke/metabolism , Stroke/pathology , Thromboxane A2/metabolism
13.
Thromb Res ; 131(4): e154-9, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23352311

ABSTRACT

UNLABELLED: Statins have demonstrated effects beyond reducing cholesterol level that may contribute to their clinical benefit, including effects on platelet biochemistry and function. OBJECTIVES: To explore and compare the antiplatelet effect of two lipophilic statins (atorvastatin and simvastatin) and one hydrophilic statin (pravastatin) concerning: a) collagen-induced platelet aggregation and thromboxane A2 (TXA2) synthesis; b) the additive effect of statins on TXA2 synthesis in platelets treated with a submaximally effective concentration of aspirin and c) the biochemical mechanisms involved. METHODS AND RESULTS: Washed human platelets were incubated with statins (1-20µM), and stimulated with collagen (1µg/ml) or arachidonic acid (AA) (200µM) and TXB2 was quantified by ELISA. Incubation with simvastatin or atorvastatin reduced (36.2% and 31.0%, respectively) collagen-induced TXB2 synthesis (p<0.05) and platelet aggregation (p<0.001), whereas pravastatin had no effects. Simultaneous incubation with a submaximally effective concentration of aspirin (1µM) and atorvastatin or simvastatin significantly increased the inhibition of TXB2 synthesis by aspirin by 4.4- and 4.1-fold, respectively. Statins did not affect AA-induced TXB2 synthesis, excluding an effect on COX-1/TXA2 synthase activities. Atorvastatin and simvastatin concentration-dependently inhibited the collagen-induced increase in cytosolic calcium and the kinetics of cPLA2 phosphorylation. Lipophilic statins reduced phosphorylation of both ERK1/2 and p38 MAPK, which regulate cPLA2 phosphorylation and calcium movement. CONCLUSION: We report for the first time a direct downregulation by atorvastatin and simvastatin of platelet cPLA2 activity through effects on calcium and MAPK, which reduce collagen-induced TXA2 synthesis. These mechanisms might contribute to their beneficial effects, even in aspirin-treated patients.


Subject(s)
Anticholesteremic Agents/pharmacology , Blood Platelets/drug effects , Blood Platelets/enzymology , Heptanoic Acids/pharmacology , Phospholipase A2 Inhibitors/pharmacology , Phospholipases A2/blood , Pyrroles/pharmacology , Simvastatin/pharmacology , Thromboxane A2/biosynthesis , Aspirin/pharmacology , Atorvastatin , Calcium/blood , Collagen/pharmacology , Cyclooxygenase 1/blood , Drug Combinations , Drug Synergism , Humans , Mitogen-Activated Protein Kinases/blood , Phosphorylation/drug effects , Platelet Aggregation/drug effects , Pravastatin/pharmacology , Thromboxane A2/blood , Thromboxane-A Synthase/blood
14.
J Stroke Cerebrovasc Dis ; 21(8): 755-9, 2012 Nov.
Article in English | MEDLINE | ID: mdl-21550266

ABSTRACT

BACKGROUND: Platelet function of patients with subarachnoid hemorrhage (SAH) may play an important part in both rebleeding and delayed cerebral ischemia, but little is known about aggregation pathways during the acute phase of stroke. Analgesics are used regularly in the first days after bleeding, and some can potentially inhibit the cyclooxygenase (COX) enzyme. We examined the platelet function of patients with SAH in order to describe their basal situation and determine whether the administration of intravenous nonsteroidal antiinflammatory drugs (NSAIDs) affected platelet aggregation. METHODS: Arachidonic acid (AA)-induced aggregation and the platelet function analyzer (PFA)-100 test with collagen/epinephrine cartridges were used to study a group of SAH patients that was treated with dexketoprofen and dipyrone and to compare them to patients that had received no analgesia. RESULTS: Ninety-six consecutive SAH patients prospectively enrolled in platelet studies. Twenty-seven patients were taking NSAIDs (10 on dexketoprofen and 17 on dipyrone), and there were 15 cases in the control group. AA-induced aggregation was 10% ± 3.2% for NSAIDs (mean ± standard error), specifically 17.2% ± 7% for dexketoprofen and 5.7% ± 1% for dipyrone. Aggregation in the control group was 72.4% ± 6% (P = .001). Both analgesics slowed the platelet plug formation during the PFA-100 test, with closure times of 237.2 ± 25 seconds for dexketoprofen and 198.4 ± 22 seconds for dipyrone and 138.1 ± 21 seconds in controls (P = .02). CONCLUSIONS: The administration of COX-inhibiting analgesics leads to an hypoaggregability state in the first days of SAH. Further insight into their impact on complications such as rebleeding and delayed cerebral ischemia is needed in order to optimize the headache treatment of SAH.


Subject(s)
Aminopyrine/therapeutic use , Blood Platelets/drug effects , Cyclooxygenase Inhibitors/therapeutic use , Headache/drug therapy , Ketoprofen/therapeutic use , Platelet Aggregation/drug effects , Subarachnoid Hemorrhage/drug therapy , Aminopyrine/adverse effects , Blood Platelets/enzymology , Case-Control Studies , Chi-Square Distribution , Cyclooxygenase Inhibitors/adverse effects , Female , Headache/blood , Headache/enzymology , Headache/etiology , Humans , Ketoprofen/adverse effects , Male , Middle Aged , Platelet Function Tests , Prospective Studies , Recurrence , Subarachnoid Hemorrhage/blood , Subarachnoid Hemorrhage/complications , Subarachnoid Hemorrhage/enzymology , Time Factors , Treatment Outcome
17.
Thromb Haemost ; 105(4): 663-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21301784

ABSTRACT

Aspirin treatment is essential in patients with acute myocardial infarction (AMI) to block platelet thromboxane (TXA)2 synthesis. Epinephrine is known to enhance platelet reactivity induced by other agonists and to be elevated in patients with AMI due to stress. Our objective was to study the influence of epinephrine on platelet TXA2 synthesis in patients treated with aspirin for AMI at early onset (within 48 hours) and the potential biochemical mechanisms involved in the functional response. Washed platelets from 45 patients with AMI and 10 aspirin-free controls were stimulated with arachidonic acid (AA) or AA + epinephrine, and aggregation and TXA2 synthesis were evaluated. Full platelet aggregation was recorded in 8/45 patients (18%) with a partial TXA2 inhibition (86%) vs. the aspirin-free controls. Platelets from the remaining 37 patients did not aggregate to AA and had TXA2 inhibition >95%. However, when platelets were simultaneously stimulated with AA + epinephrine, in 25/37 patients a large intensity of aggregation (73%) was observed and a 5.5-fold increase in TXA2 synthesis, although this remained residual (<5% of aspirin-free controls). This residual-TXA2 was critical in the functional response, as demonstrated by the complete inhibition by TXA2 receptor blockade or additional aspirin in vitro. The phosphatidylinositol-3-kinase activity and the cytosolic calcium levels participated in this platelet response elicited by a receptor cooperation mechanism, while the Rho/p160(ROCK) pathway or the blockade of the ADP receptors (P2Y1, P2Y12) were without effect. Residual-cyclooxygenase -1 activity and epinephrine enhance TXA2-dependent platelet function, which may reduce the clinical benefit of aspirin in patients with AMI.


Subject(s)
Aspirin/therapeutic use , Blood Platelets/drug effects , Cyclooxygenase 1/metabolism , Epinephrine/pharmacology , Myocardial Infarction/drug therapy , Adult , Aged , Aged, 80 and over , Arachidonic Acid/pharmacology , Aspirin/administration & dosage , Blood Platelets/metabolism , Blood Platelets/pathology , Calcium Signaling/drug effects , Cells, Cultured , Drug Interactions , Female , Humans , Male , Middle Aged , Myocardial Infarction/blood , Phosphatidylinositol 3-Kinases/metabolism , Platelet Aggregation/drug effects , Platelet Aggregation Inhibitors/therapeutic use , Thromboxane A2/biosynthesis
18.
Am J Cardiol ; 104(12): 1618-23, 2009 Dec 15.
Article in English | MEDLINE | ID: mdl-19962464

ABSTRACT

Inhibition of platelet thromboxane A(2) (TXA(2)) by aspirin is critical in patients with acute myocardial infarction (AMI), but some patients have persistent platelet TXA(2) production within 48 hours of the onset of AMI. Statins are known to reduce TXA(2) in aspirin-free patients with hypercholesterolemia. We hypothesized that treatment with aspirin plus atorvastatin could reduce persistent TXA(2) synthesis and aspirin resistance in patients with AMI. We evaluated platelet function in 184 aspirin-treated patients within 48 hours of the onset of AMI. Patients were divided into group A (treated with aspirin alone, n = 139) and group B (treated with aspirin plus atorvastatin, n = 45). We studied collagen-induced platelet TXA(2) synthesis, serotonin ((14)C-5HT) release and recruitment, and adenosine diphosphate-, arachidonic acid-, and collagen-induced platelet aggregation. Persistent TXA(2) synthesis was detected in 25% and 9% of groups A and B, respectively (p = 0.03). TXA(2), arachidonic acid-aggregation, and collagen-induced responses were significantly reduced in patients receiving dual treatment compared to those receiving aspirin monotherapy. Atorvastatin did not modify platelet reactivity in patients with efficiently blocked TXA(2) synthesis. These results strongly suggest a direct effect of the statin on platelet eicosanoid synthesis. This was confirmed in vitro by incubating washed aspirin-free and aspirin (1 muM)-treated platelets from normal subjects with 1 to 20 microM atorvastatin. Atorvastatin in vitro significantly reduced platelet TXA(2) synthesis and collagen-induced aggregation. In conclusion, atorvastatin combined with aspirin early in the onset of the acute event significantly reduced persistent TXA(2) and TXA(2)-dependent aspirin resistance. This could contribute to the clinical benefit of atorvastatin in patients with AMI.


Subject(s)
Aspirin/pharmacology , Blood Platelets/drug effects , Heptanoic Acids/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Pyrroles/pharmacology , Thromboxane A2/blood , Adult , Aged , Aged, 80 and over , Aspirin/therapeutic use , Atorvastatin , Drug Therapy, Combination , Female , Heptanoic Acids/therapeutic use , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Male , Middle Aged , Myocardial Infarction/drug therapy , Pyrroles/therapeutic use , Treatment Outcome
19.
Am J Cardiol ; 99(1): 19-25, 2007 Jan 01.
Article in English | MEDLINE | ID: mdl-17196455

ABSTRACT

Heterogeneity in response to aspirin (ASA) treatment, or "aspirin resistance," could be of importance in patients with ST-segment elevation myocardial infarction (STEMI). Decreased effects of ASA in platelets could be due to partial inhibition of cyclo-oxygenase-1 (COX-1) or to COX-1-independent mechanisms. We evaluated the effect of ASA treatment in patients with STEMI for (1) platelet thromboxane A(2) (TXA(2)) synthesis, (2) platelet recruitment elicited by TXA(2)-dependent and -independent mechanisms, and (3) a possible association of these aspects of platelet reactivity with serum markers of myonecrosis. We studied 62 ASA-treated patients within 48 hours of onset of the acute event and 69 ASA-free and 10 ASA-treated controls. TXA(2) synthesis and platelet recruitment (fluid-phase proaggregate activity of cell-free releasate) were assessed after collagen stimulation (1 micro g/ml) of whole blood. Partial inhibition of TXA(2) by ASA was found in 21 patients (34%). This was associated with significant increases in troponin T, creatine kinase-MB mass, creatine kinase, and recruiting activity versus 41 patients with blocked TXA(2) production. This was independent of fibrinolysis, and platelet COX-2 expression was not augmented. TXA(2) blockade was achieved after subsequent daily treatments or platelet incubation with ASA in vitro, suggesting lower sensitivity of COX-1 to ASA. In addition, 28 patients (45%) had an abnormally increased recruiting activity despite TXA(2) blockade, which was also associated with increased myonecrosis. In conclusion, ASA resistance, elicited by TXA(2)-dependent and TXA(2)-independent mechanisms, was prevalent in patients with STEMI. This study describes, for the first time, the association of partial platelet TXA(2) inhibition with myonecrosis.


Subject(s)
Aspirin/therapeutic use , Blood Platelets/physiology , Myocardial Infarction/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Thromboxane A2/blood , Adult , Aged , Aged, 80 and over , Aspirin/administration & dosage , Case-Control Studies , Drug Resistance , Female , Humans , Male , Middle Aged , Myocardial Infarction/blood , Myocardial Infarction/enzymology , Myocardial Infarction/pathology , Myocardium/pathology , Necrosis , Platelet Aggregation/physiology , Platelet Aggregation Inhibitors/administration & dosage , Severity of Illness Index
20.
Platelets ; 17(6): 405-15, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16973502

ABSTRACT

Platelet thromboxane A2 (TXA2) synthesis is an important pathway of platelet reactivity. We report that in thrombin-stimulated platelets, PP1/PP2A serine/threonine phosphatases regulate phospholipase A2 (cPLA2) activity, which is required for TXA2 synthesis. Two mechanisms are involved: (a) constitutively active PP1/PP2A regulate cPLA2 phosphorylation, and (b) PP1/PP2A activity mediates agonist-induced increase in cytosolic Ca2+ ([Ca2+]i). Inhibition of PP1/PP2A with okadaic acid (OA) induces cPLA2 phosphorylation but reduces Ca2+ responses: release from intracellular stores and influx through the plasma membrane, particularly that mediated by store-mediated Ca2+ entry (SMCE). A significant correlation (r = 0.64) exists between OA-regulated [Ca2+]i and TXA2 synthesis. Okadaic acid-induced decrease in SMCE and the associated TXA2 synthesis are mediated by a reduction in protein-tyrosine phosphorylation. This reduction is not due to inhibition of tyrosine kinases but rather to an OA-mediated increase in tyrosine phosphatases. This is the first study to report that PP1/PP2A phosphatases are involved in the regulation of the two key elements in eicosanoid synthesis, [Ca2+]i and cPLA2 phosphorylation. Moreover, PP1/PP2A regulation of [Ca2+]i and tyrosine phosphorylation may be important for other calcium-dependent processes and/or signal transduction mechanisms in platelets.


Subject(s)
Blood Platelets/enzymology , Calcium/metabolism , Phospholipases A/metabolism , Phosphoprotein Phosphatases/metabolism , Thromboxane A2/metabolism , Cytosol/enzymology , Group IV Phospholipases A2 , Humans , In Vitro Techniques , Okadaic Acid/pharmacology , Phospholipases A2 , Phosphorylation , Platelet Aggregation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...